Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: IT'S PREMATURE!

Re: IT'S PREMATURE! B-lunist borredo1

posted on Jan 09, 2009 03:04AM

You can't be serious?



Please look at the date of your article: shs decreased by 1 for 10 split Oct 10, 2000

Now please take the time to read POPM's 10K

The Company had a working capital deficit of $5,545,000 at December 31, 2000, (net of assets held for sale). Cash and equivalents were $20,000 at December 31, 2000, representing a decrease of approximately $1,116,000 from the cash and equivalents of $1,136,137 at January 2, 2000. The Company's ability to continue its present operations and successfully implement future expansion plans is contingent upon its ability to raise additional capital, increase its revenues, and ultimately attain and sustain profitable operations. Without additional financing, the cash generated from the Company's current operations will not be adequate to fund operations and service its indebtedness during 2001. Management intends to continue to raise additional capital to fund the ongoing operations of the Company. However, there can be no assurance that additional financing will be available on terms acceptable to the Company or on any terms whatsoever. In the event the Company is unable to fund its operations and its business plan, it will be unable to continue as a going concern.

We incurred net losses of approximately $122.5 million in 2000 and $24.2 million in 1999, and had a working capital deficit of approximately $5.5 million as of December 31, 2000

http://www.pinksheets.com/edgar/GetF...

I couldn't agree more with your opinion as to this Company:

The consideration of a reverse split smacks of desperation. IMO

Now, please have a look at the 3 Companies I've given (MSTR, JCOM, and IHR) and let me know if you can see any glaring differences.

Were they desperate too?

Be well

Share
New Message
Please login to post a reply